Supplement withdrawal is the rebound or discontinuation response that appears after the body has adapted to a compound taken at a meaningful dose for long enough to shift receptor density, enzyme activity, or hormonal feedback. It is not present for every supplement, and it is not the same as an adverse event, but when it does appear it can be sharp enough to be mistaken for illness, anxiety, or a new condition.
Why withdrawal is often missed
Users rarely plan for withdrawal because the dominant framing is adding compounds, not stopping them. A caffeine headache on the second day off coffee, sleep returning to baseline after stopping nightly melatonin, or three weeks of flat mood after dropping a long-running ashwagandha dose all get blamed on external causes when the pattern is pharmacological. Building a stop condition into the plan before the first dose turns those surprises into expected data points that can be cross-checked against a baseline.
Compounds most likely to show withdrawal
| Class | Typical symptom | Expected onset | Expected duration |
|---|---|---|---|
| Caffeine (>200 mg/day) | Headache, fatigue, low mood, poor focus | 12–36 hours | 2–9 days |
| Nicotine (any route) | Irritability, craving, appetite increase | 4–24 hours | 2–4 weeks |
| Melatonin (>1 mg nightly) | Sleep may return to prior baseline | Variable | Variable |
| Ashwagandha (>600 mg x 8 wk) | Flat mood, mild anxiety rebound | 3–10 days | 1–3 weeks |
| Exogenous ketones or MCT | Transient fatigue, hunger swings | 1–3 days | 3–7 days |
| Kratom, CBD at high daily use | GI upset, restlessness, sleep disruption | 12–72 hours | 3–14 days |
Compounds like vitamin D, creatine, and omega-3 do not produce classical withdrawal. Their benefit simply fades as tissue stores return to baseline over weeks.
Taper rather than cold stop
A downward titration protects the receptor systems that adapted to the daily dose. A workable default is a 25–50% reduction every 4–7 days until the dose is negligible, then stop. Caffeine tapered from 300 mg to 150 mg to 75 mg to 0 over two weeks typically eliminates the headache phase entirely. For melatonin, a lower dose or planned stop can show whether sleep returns to its pre-supplement baseline. A sharp stop is only appropriate when the compound is causing an adverse event, in which case a clinician should be in the loop.
What to log during a planned stop
During the discontinuation window, three fields do most of the diagnostic work:
- Sleep onset and total sleep time each night.
- A 1–10 subjective energy score and mood score each morning.
- A free-text tag for any symptom that appears, with date and severity.
Seven to fourteen days of clean data after the last dose gives a credible read on true post-supplement baseline, which is the whole point of a washout period in n-of-1 work.
Distinguishing withdrawal from adverse event
Withdrawal symptoms follow the stop, peak within the first week, and fade on a predictable curve. An adverse event either began while still dosing or does not follow that curve. Severe, escalating, or cardiovascular, hepatic, renal, or psychiatric symptoms after stopping are not normal withdrawal and need clinical attention regardless of the supplement involved.
How this appears in Unfair
Unfair prompts for a taper plan when a user removes a compound tagged as taper-recommended, and it surfaces an expected symptom window based on the class, prior dose, and duration of use. The log view flags the first 14 days after a stop as a sensitive period so dips in energy, sleep, or mood are attributed to the change rather than to unrelated noise, and overlap with a new compound is held back until the window closes.
Clinical safety note
Seek urgent care for chest pain, severe hypertension or hypotension, seizures, confusion, suicidal thoughts, or withdrawal-like symptoms that persist beyond two weeks or escalate rather than fade. Discontinuation of a supplement that was taken alongside psychiatric, cardiovascular, or seizure medication should be done with the prescribing clinician informed in advance.